Fig. 5
(Reproduced under the terms of the CC-BY 4.0. Copyright 2020, The Authors, published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles)
Targeted delivery of PTX by enzymatically conjugated RBCEVs for EGFR+ lung cancer treatment [156]. A Schematic diagram of the conjugation between biotin modified ET-NGL peptide (bi-EL-NGL) and GL containing EV (GL-EV) by OaAEP1 ligase. B Distribution of intravenously administrated uncoated RBCEVs, Cont-coated RBCEVs and ET-coated RBCEVs (DiR labeling) in different organs from EGFR+ lung cancer xenografted mouse model by IVIS imaging. C H&E staining and TUNEL assay of lung sections from EGFR+ lung cancer xenografted mouse model with the administration of PTX, PTX delivered by uncoated RBCEVs, PTX delivered by Cont-coated RBCEVs, and PTX delivered by ET-coated RBCEVs (TUNEL, green; Cell nucleus, blue; Scale bar = 100 μm)